gms | German Medical Science

22nd Annual Meeting of the German Retina Society

German Retina Society

26.06. - 27.06.2009, Berlin

Article

Send article

Triesence® or purified Volon A® – What is the difference?

Meeting Abstract

Search Medline for

  • Martin S. Spitzer - University Eye Clinic of Tuebingen
  • F. Ziemssen - University Eye Clinic of Tuebingen
  • K. Rinker - University Eye Clinic of Tuebingen
  • K. U. Bartz-Schmidt - University Eye Clinic of Tuebingen
  • Peter Szurman - University Eye Clinic of Tuebingen

German Retina Society. 22nd Annual Meeting of the German Retina Society. Berlin, 26.-27.06.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. DocRG2009-11

doi: 10.3205/09rg11, urn:nbn:de:0183-09rg118

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/meetings/rg2009/09rg11.shtml

Published: June 29, 2009

© 2009 Spitzer et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Background: Intravitreal injections of triamcinolone are not only an important therapeutic tool for a variety of vitreo-retinal disorders, but can also be employed for visualization of the vitreous during pars plana vitrectomy. Triesence® is a preservative-free triamcinolone suspension that has been approved for visualization during vitrectomy via intravitreal administration and for intravitreal therapy of certain rare ocular diseases. However, the differences between Triesence® and purified (and thus also preservative-free) triamcinolones such as Volon A® or Kenalog® are not well specified, although the manufacturer of Triesence® advertises the product as „specifically formulated for the eye“.

Methods: Triesence ® , Kenalog® or purified triamcinolone (Volon-A®) (1–0.01 mg/ml) was added either directly on top or separated by a Boyden chamber filter to confluent cell cultures of retinal pigment epithelium (ARPE19) or retinal ganglion cells (RGC5). Cell viability was assessed using MTT-ELISA and Live/Dead®-Assay. The publicly available FDA application material for Triesence® was searched in respect to the differences between Triesence® and older triamcinolone preparations.

Results: Sedimentation of Triesence®, Kenalog® or purified Volon-A® caused a pronounced decrease of cell viability. Cytotoxicity was most pronounced when Triesence® was used. Without direct sedimentation of triamcinolone crystals on top of cells one of the three formulations was cytotoxic. According to the publicly available FDA documents the approval of Triesence was due to studies that mainly have been conducted with Kenalog® or purified Volon-A®. Apart from intraoperative use during vitrectomy Triesence® has only been approved for sympathetic ophthalmia, temporal arteriitis, and ocular conditions unsresponsive to topical steroids. Consequently, the use of Triesence® like the older triamcinolone preparations (Kenalog® or Volon-A®) for diabetic macular edema, for Irivine-Gass syndrome, for neovascular AMD or after retinal vein occlusion is off-label.

Conclusion: The main difference between Triesence® and purified triamcinolone formulations seems to be the significantly higher price of Triesence®. Direct contact between retinal cells and Triesence® particles should be avoided.